Form 4: Beam Therapeutics Chief Medical Officer Sells Shares Under Pre-Arranged Trading Plans
Insider Transaction Report
Beam Therapeutics' Chief Medical Officer, Amy Simon, reported the sale of 1,250 shares of common stock in early July 2025 through pre-arranged Rule 10b5-1 trading plans.
Summary
- Amy Simon, Chief Medical Officer of Beam Therapeutics Inc. (BEAM), reported two sales of common stock in July 2025.
- On July 1, 2025, 374 shares were sold at $16.9423 per share to cover tax withholding obligations related to the vesting of restricted stock units granted on June 30, 2022.
- On July 3, 2025, an additional 876 shares were sold at $20.12 per share.
- Both sales were executed under Rule 10b5-1 trading plans, adopted on May 19, 2023, and November 7, 2024, respectively.
- Following these transactions, Amy Simon beneficially owns 64,864 shares of Beam Therapeutics common stock.
- The reported holdings also include 372 shares acquired under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2024.
Sentiment
Score: 5
Explanation: The transactions are routine insider sales, largely pre-planned and partly for tax purposes, which typically do not indicate strong positive or negative sentiment about the company's future performance.
Positives
- Sales were conducted under pre-arranged Rule 10b5-1 trading plans, indicating a planned, non-discretionary divestment rather than an immediate reaction to new information.
- One sale was specifically for tax withholding obligations upon the vesting of restricted stock units, which is a common and expected event for equity compensation.
Negatives
- An insider, the Chief Medical Officer, sold a total of 1,250 shares of common stock.
- The sales reduce the insider's direct beneficial ownership in the company.
Future Outlook
NA
Industry Context
This Form 4 filing details routine insider stock transactions by a Chief Medical Officer in the biotechnology sector. Such transactions, particularly those under Rule 10b5-1 plans or for tax purposes, are common and do not inherently reflect broader industry trends or specific company performance beyond the individual's equity compensation and financial planning.
Related Party Transactions
- The sales of common stock by Amy Simon, Chief Medical Officer, are transactions by a related party (an officer of the company). These were market sales of company equity.
Stakeholder Impact
- Shareholders: The sale of shares by a key executive could be perceived negatively by some, but the pre-planned nature and tax-related reason for one sale mitigate this. It slightly increases the float of shares available in the market.
Key Dates
| Date | Description |
|---|---|
| 2022-06-30 | Date of grant of certain restricted stock units to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan. |
| 2023-05-19 | Date the Reporting Person adopted a Rule 10b5-1 trading plan for the sale of shares related to tax withholding obligations. |
| 2024-09-30 | Date 372 shares were acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan. |
| 2024-11-07 | Date the Reporting Person adopted a Rule 10b5-1 trading plan for the sale of 876 shares. |
| 2025-07-01 | Date of sale of 374 shares of common stock at $16.9423 to cover tax withholding obligations. |
| 2025-07-03 | Date of sale of 876 shares of common stock at $20.12. |
Recommendation
holdKeywords
Beam Therapeutics, BEAM, SEC Form 4, Insider Trading, Stock Sale, Amy Simon, Chief Medical Officer, Rule 10b5-1, Restricted Stock Units, Equity Incentive Plan, Employee Stock Purchase Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.